In 2030, the domestic in vitro diagnostic market will reach 288.2 billion yuan, and the space to replace the import of high-end production equipment is to be opened

[Pharmaceutical Network Market Analysis] In vitro diagnosis (IVD) refers to products and services that obtain clinical diagnostic information by testing human samples (blood, body fluids, tissues, etc.
) outside the human body, and then judge diseases or body functions
.

At present, in vitro diagnosis plays an increasingly prominent role in the prevention, diagnosis and treatment of human diseases, and has become an increasingly important part of ensuring human health
.

 In 2030, the domestic in vitro diagnostic market will reach 288.
2 billion yuan (Source: Pharmaceutical Network) It is understood that the upstream of the in vitro diagnostic industry is the core components of electronic components, molds and other instruments, as well as antigen, antibody, enzyme and other reagent raw material enterprises
.

Since the quality of reagent raw materials will affect the quality of in vitro diagnosis, the development of these reagent raw materials industries such as antigens and antibodies is of key significance to the development of the entire in vitro diagnosis industry
.

The midstream includes R&D and production enterprises of instruments and consumables, as well as distribution enterprises
.

At present, foreign in vitro diagnostic giants already have strong capabilities in the production of diagnostic reagents and instruments, while domestic companies, due to their late start and low overall technical level, mainly focus on the production of reagents, and only a few companies can develop high-end equipment
.

Downstream are hospitals, blood stations, third-party inspection centers, physical examination centers and other end-user-oriented medical testing institutions
.

In recent years, with the promotion of policies such as medical reform and medical insurance cost control, the third-party testing industry has shown a rapid development momentum, and the market scale has continued to expand.
In 2020, the market size of the third-party testing and testing industry has reached more than 140 billion yuan
.

What needs to be seen is that the number of private enterprises is increasing.
By the end of 2019, there were about 23,000 private quality inspection institutions in China, accounting for half of the total, an increase of 3.
45 percentage points from the previous year
.

 　　With the aggravation of aging, the enhancement of people's health awareness, and the continuous development of diagnostic technology, the global in vitro diagnostic industry has broad prospects for development, and the market size will continue to expand
.

Relevant data show that in 2019, the global in vitro diagnostic industry was about 68.
8 billion US dollars.
It is expected that the global in vitro diagnosis market will exceed 130 billion US dollars in 2030, and the annual compound growth rate from 2019 to 2030 is expected to be about 6.
0%
.

 　　Looking at the domestic market, in 2019, China's in vitro diagnostic market accounted for about 18% of the global market, which is far from the proportion of nearly 60% in Europe, America, Japan and South Korea
.

Since 2020, the domestic in vitro diagnostic industry has developed rapidly.
With the introduction of a series of favorable policies, the innovation and research and development of local enterprises will continue to increase, and the pace of substitution of domestic products for imports will continue to accelerate.
will continue to improve
.

Data shows that in 2019, the scale of China's in vitro diagnostics market was 80 billion yuan.
It is expected that the Chinese market will increase to 288.
2 billion yuan by 2030, and its proportion in the global market will increase to more than 33%, with huge growth potential
.

 　　With the domestic in vitro diagnostic market ushering in considerable prospects, the industry expects that the instruments and consumables industries related to the in vitro diagnostic industry chain are also expected to gain development opportunities, especially in the field of high-end production equipment, there is still a lot of room for import substitution to be opened
.

Domestic equipment companies need to continue to increase investment in research and development, overcome the "stuck neck" link, and develop products with independent property rights to meet the needs of the domestic medical market
.

 　　The author has noticed that recently, investors have also paid close attention to the situation of companies that may involve in vitro diagnostic production equipment
.

 　　For example, on March 3, Kerui Technology mentioned on the interactive platform that in the field of IVD, the company will carry out certain technical reserves, and will plan in the future based on changes in market demand
.

It is understood that in the medical and health field, the main product of Kerui Technology is the automatic filling line equipment for in vitro diagnostic reagents (IVD), but it currently accounts for a small amount of the company's overall revenue
.

 　　On March 16, some investors also asked whether Chutian Technology has filling equipment and orders for the production of in vitro diagnostic products
.

Unfortunately, Chutian Technology responded that the company is currently focusing on overall solutions for pharmaceutical equipment and processes
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.